• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.

作者信息

Claassens Eva L, Ploumen Roxanne A W, van Nijnatten Thiemo J A, Smidt Marjolein L

机构信息

Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.

Department of Surgery, Maastricht University Medical Center+, Maastricht, the Netherlands; GROW - Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.

出版信息

Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.

DOI:10.1016/j.breast.2025.104467
PMID:40204577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12144931/
Abstract
摘要

相似文献

1
Reaction to 'addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC'.对“解决三阴性乳腺癌中导管原位癌对新辅助化疗反应研究的关键局限性”的回应
Breast. 2025 Jun;81:104467. doi: 10.1016/j.breast.2025.104467. Epub 2025 Apr 4.
2
Addressing key limitations in the study on DCIS response to neoadjuvant chemotherapy in TNBC.解决三阴性乳腺癌中导管原位癌对新辅助化疗反应研究中的关键局限性。
Breast. 2025 Jun;81:104466. doi: 10.1016/j.breast.2025.104466. Epub 2025 Apr 4.
3
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.预测三阴性乳腺癌新辅助化疗反应的基线因素及其对非手术治疗的影响。
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.
4
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.新辅助化疗对三阴性乳腺癌患者导管原位癌的影响：一项全国性分析。
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
5
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.托瑞帕利单抗联合化疗治疗转移性或复发性三阴性乳腺癌的TORCHLIGHT试验结果的通俗语言总结。
Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4.
6
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.三阴性乳腺癌中 p53 表达对化疗预后和疗效的影响差异。
Breast Cancer Res Treat. 2018 Nov;172(2):437-444. doi: 10.1007/s10549-018-4928-2. Epub 2018 Aug 21.
7
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.治疗前活检中存在原位成分与乳腺癌新辅助化疗的反应无关。
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
8
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.导管原位癌伴发癌对新辅助全身治疗的病理反应：一项系统评价
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
9
Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.新辅助化疗联合免疫检查点抑制剂治疗三阴性乳腺癌的疗效与安全性：一项随机对照试验的荟萃分析
Front Oncol. 2021 Nov 29;11:657634. doi: 10.3389/fonc.2021.657634. eCollection 2021.
10
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.乳腺癌新辅助化疗后的病理完全缓解和残留导管原位癌
Br J Cancer. 2006 Feb 13;94(3):358-62. doi: 10.1038/sj.bjc.6602950.

本文引用的文献

1
The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis.新辅助化疗对三阴性乳腺癌患者导管原位癌的影响：一项全国性分析。
Breast. 2025 Apr;80:104425. doi: 10.1016/j.breast.2025.104425. Epub 2025 Feb 18.
2
Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.新辅助全身治疗后乳腺癌患者导管原位癌反应评估的影像学发现：系统评价和荟萃分析。
Eur Radiol. 2023 Aug;33(8):5423-5435. doi: 10.1007/s00330-023-09547-7. Epub 2023 Apr 5.
3
Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.导管原位癌伴发癌对新辅助全身治疗的病理反应：一项系统评价
Cancers (Basel). 2022 Dec 20;15(1):13. doi: 10.3390/cancers15010013.
4
The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer.治疗前活检中存在原位成分与乳腺癌新辅助化疗的反应无关。
Cancers (Basel). 2021 Jan 10;13(2):235. doi: 10.3390/cancers13020235.
5
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.预测三阴性乳腺癌新辅助化疗反应的基线因素及其对非手术治疗的影响。
Br J Surg. 2018 Apr;105(5):535-543. doi: 10.1002/bjs.10755. Epub 2018 Feb 21.